← All trials
NCT05580666
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2023
- Primary completion
- Aug 31, 2026
- Completion date
- Dec 31, 2026
- First posted
- Oct 14, 2022
- Last posted
- Oct 14, 2022
- Enrollment
- 8000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- McMaster UniversityLead sponsor
- McMaster UniversityOverall official - principal investigator
- University of Cape TownOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.